Evidence map›Paper›PMID 32947881›Full record

ArticleCells2020

In Vitro Characterization of Gut Microbiota-Derived Commensal Strains: Selection of

Bernardo Cuffaro, Aka L W Assohoun, Denise Boutillier, Lenka Súkeníková, Jérémy Desramaut, Samira Boudebbouze, Sophie Salomé-Desnoulez, Jiří Hrdý, Anne-Judith Waligora-Dupriet, Emmanuelle Maguin and 1 more

Abstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Trial
  2. Article
  3. Virulence · 2026
    Article
  4. Postbiotic potential of heat-inactivated Limosilactobacillus reuteri and its cell-free supernatant in protecting intestinal health of zebrafish.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Draft genome sequence ofMicrobiology resource announcements · 2025
    Article
  11. Article
  12. Article
  13. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bernardo CuffaroUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, 59000 Lille, France.
Aka L W AssohounInstitut Micalis, MIHA Team, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France.
Denise BoutillierUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, 59000 Lille, France.
Lenka SúkeníkováInstitute of Immunology and Microbiology, First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech Republic.
Jérémy DesramautUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, 59000 Lille, France.
Samira BoudebbouzeInstitut Micalis, MIHA Team, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France.
Sophie Salomé-DesnoulezUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UMS 2014-PLBS, 59000 Lille, France.
Jiří HrdýInstitute of Immunology and Microbiology, First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech Republic.ORCID 0000-0003-0612-4509
Anne-Judith Waligora-DuprietUMR-S1139 INSERM, Faculté de Pharmacie de Paris, Université de Paris, 75006 Paris, France.
Emmanuelle MaguinInstitut Micalis, MIHA Team, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France.ORCID 0000-0001-5452-3382
Corinne GrangetteUniversité de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, 59000 Lille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in the gut microbiota composition and diversity seem to play a role in the development of chronic diseases, including inflammatory bowel disease (IBD), leading to gut barrier disruption and induction of proinflammatory immune responses. This opens the door for the use of novel health-promoting bacteria. We selected five

Indexed as

AdultAnimalsBacteroidetesCaco-2 CellsColitisDisease Models, AnimalDNA, BacterialFecesFemaleGastrointestinal MicrobiomeHumansInfant, NewbornInflammatory Bowel DiseasesIntestinal MucosaMiceMice, Inbred BALB CDNA, BacterialTrinitrobenzenesulfonic Acidcolitisfunctional screeningholobiontIBDimmune responselive biotherapeutic products (LBP)microbiotaprobiotics

Identifiers

PMID32947881
PMCPMC7565435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.